Insights from 2023 ESMO Annual Meeting
ESMO 2023 Insights: "DESTINY-Breast04 Study Updated Survival Results - T-DXd vs. Treatment of Physician’s Choice in Patients With HER2-Low Unresectable and/or Metastatic Breast Cancer"
By
Insights from 2023 ESMO Annual Meeting
FEATURING
Shanu Modi
By
Insights from 2023 ESMO Annual Meeting
FEATURING
Shanu Modi
Login to view comments.
Click here to Login
Breast